Annotation Detail
Information
- Associated Genes
- NTRK1
- Associated Variants
- NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS
- Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1. Both of these fusions lead to constitutive kinase activity and were found to be oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701 and, to a lesser extent, crizotinib) inhibited autophosphorylation of TRKA and cell growth.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1019
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3983
- Variant URL
- https://civic.genome.wustl.edu/links/variants/419
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib,Larotrectinib,Lestaurtinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24162815
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Larotrectinib | Sensitivity | true |
| Lestaurtinib | Sensitivity | true |
| Crizotinib | Sensitivity | true |